@conference{2531b83ed512454aa302fe2fd73baea9,
title = "Outcomes of primary central nervous system lymphoma in the era of immunotherapy: Cleveland Clinic experience.",
author = "Balasubramanian, \{Suresh Kumar\} and Philipp Schmitt and Meena Sadaps and Vidhya Karivedu and Debra Kangisser and Chao, \{Samuel T.\} and Murphy, \{Erin Sennett\} and Suh, \{John H.\} and Ahluwalia, \{Manmeet Singh\} and Singh, \{Arun D\} and Peereboom, \{David M.\}",
note = "e13516 Background: Primary central nervous system lymphoma (PCNSL), a form of extranodal non-Hodgkin lymphoma represents 3\% of primary CNS tumors. It is aggressive but typically confined to the CNS. Despite improvements in the management of PCNSL, more than 50\% of patients eventually relapse. There are limited data on PCNSL from larger cohort studies.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2017",
month = may,
day = "30",
doi = "10.1200/JCO.2017.35.15\_SUPPL.E13516",
language = "American English",
}